Management of Mevalonate Kinase Deficiency: A Pediatric Perspective

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2020 Jun 26

PMID 32582214

Citations 21

Authors

Jerold Jeyaratnam

Joost Frenkel

Affiliations

Soon will be listed here.

Abstract

Mevalonate kinase deficiency (MKD) is an inborn error of metabolism leading to a syndrome characterized by recurrent inflammation. This clinically manifests itself as fever and can be accompanied by gastrointestinal symptoms, oral ulcers, cervical lymphadenopathy, and skin rash. We searched Pubmed, Embase, Cochrane, and CINAHL for relevant articles. All articles were screened by both authors. Relevant articles were included in this review. The interleukin-1 antagonist canakinumab is the only well-studied and effective treatment for MKD patients with 35% of patients reaching complete remission in a large randomized controlled trial. Other therapeutic options include glucocorticoids and the IL-1 antagonist anakinra, although the level of evidence for these treatments is weaker. If patients fail to these treatments, the biologicals etanercept or tocilizumab can be used. Mildly affected patients might benefit from cheaper, less invasive treatments such as paracetamol and NSAIDs. Canakinumab is the only evidence-based treatment for mevalonate kinase deficiency. However, the costs limit availability for many patients. Cheaper and more readily available options include glucocorticoids, anakinra, etanercept, and tocilizumab, although there is limited evidence supporting these treatments.

Citing Articles

The Golden Card of Interleukin-1 Blockers in Systemic Inflammasomopathies of Childhood.

Rigante D Int J Mol Sci. 2025; 26(5).

PMID: 40076498 PMC: 11899952. DOI: 10.3390/ijms26051872.

Intrauterine intestinal obstruction in a preterm infant with severe mevalonate kinase deficiency - a case report.

Hoermann H, Franzel J, Tautz J, Oommen P, Lainka E, Mayatepek E Matern Health Neonatol Perinatol. 2025; 11(1):8.

PMID: 40038796 PMC: 11881282. DOI: 10.1186/s40748-025-00207-w.

Complex MEFV and MVK Variations in a Syrian Child: Implications for Clinical Phenotypes and Treatment Response-A Case Report.

Kousa A, Ahmed R, Abu Bakr M, Aldosh A, Khalil B J Investig Med High Impact Case Rep. 2024; 12:23247096241291929.

PMID: 39417850 PMC: 11528672. DOI: 10.1177/23247096241291929.

The Etiologic Landscape of Lymphoproliferation in Childhood: Proposal for a Diagnostic Approach Exploring from Infections to Inborn Errors of Immunity and Metabolic Diseases.

Costagliola G, De Marco E, Massei F, Roberti G, Catena F, Casazza G Ther Clin Risk Manag. 2024; 20:261-274.

PMID: 38770035 PMC: 11104440. DOI: 10.2147/TCRM.S462996.

Fluvastatin Converts Human Macrophages into Foam Cells with Increased Inflammatory Response to Inactivated .

Montero-Vega M, Matilla J, Bazan E, Reimers D, De Andres-Martin A, Gonzalo-Gobernado R Cells. 2024; 13(6.

PMID: 38534380 PMC: 10969755. DOI: 10.3390/cells13060536.

References

Mandey S, Kuijk L, Frenkel J, Waterham H . A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum. 2006; 54(11):3690-5. DOI: 10.1002/art.22194. View

Ozen S, Kuemmerle-Deschner J, Cimaz R, Livneh A, Quartier P, Kone-Paut I . International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care Res (Hoboken). 2016; 69(4):578-586. DOI: 10.1002/acr.23120. View

De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman H . Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med. 2018; 378(20):1908-1919. DOI: 10.1056/NEJMoa1706314. View

Park Y, Wood G, Kastner D, Chae J . Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol. 2016; 17(8):914-21. PMC: 4955684. DOI: 10.1038/ni.3457. View

Dougados M, Betteridge N, Burmester G, Euller-Ziegler L, Guillemin F, Hirvonen J . EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis. 2004; 63(9):1172-6. PMC: 1755117. DOI: 10.1136/ard.2004.023697. View

Yang Y, Wang H, Kouadir M, Song H, Shi F . Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019; 10(2):128. PMC: 6372664. DOI: 10.1038/s41419-019-1413-8. View

Lane T, Gillmore J, Wechalekar A, Hawkins P, Lachmann H . Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. Clin Exp Rheumatol. 2015; 33(6 Suppl 94):S46-53. View

Skinner O, Jurczyluk J, Baker P, Masters S, Rios Wilks A, Clearwater M . Lack of protein prenylation promotes NLRP3 inflammasome assembly in human monocytes. J Allergy Clin Immunol. 2019; 143(6):2315-2317.e3. DOI: 10.1016/j.jaci.2019.02.013. View

Ter Haar N, Jeyaratnam J, Lachmann H, Simon A, Brogan P, Doglio M . The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. Arthritis Rheumatol. 2016; 68(11):2795-2805. DOI: 10.1002/art.39763. View

10.

Neven B, Valayannopoulos V, Quartier P, Blanche S, Prieur A, Debre M . Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl J Med. 2007; 356(26):2700-3. DOI: 10.1056/NEJMoa070715. View

11.

Musters A, Tak P, Baeten D, Tas S . Anti-interleukin 6 receptor therapy for hyper-IgD syndrome. BMJ Case Rep. 2015; 2015. PMC: 4636692. DOI: 10.1136/bcr-2015-210513. View

12.

Deshayes S, Georgin-Lavialle S, Hot A, Durel C, Hachulla E, Rouanes N . Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review. J Rheumatol. 2018; 45(3):425-429. DOI: 10.3899/jrheum.170684. View

13.

Reboldi A, Dang E, McDonald J, Liang G, Russell D, Cyster J . Inflammation. 25-Hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon. Science. 2014; 345(6197):679-84. PMC: 4289637. DOI: 10.1126/science.1254790. View

14.

Erdol S, Cekic S, Caki Kilic S, Saglam H, Kilic S . Massive ascites in a canakinumab resistant case with MVA leading to bone marrow transplantation. Rheumatol Int. 2016; 36(7):1011-3. DOI: 10.1007/s00296-016-3456-9. View

15.

van der Hilst J, Bodar E, Barron K, Frenkel J, Drenth J, van der Meer J . Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore). 2008; 87(6):301-310. DOI: 10.1097/MD.0b013e318190cfb7. View

16.

Shendi H, Devlin L, Edgar J . Interleukin 6 blockade for hyperimmunoglobulin D and periodic fever syndrome. J Clin Rheumatol. 2014; 20(2):103-5. DOI: 10.1097/01.RHU.0000442576.41537.de. View

17.

Arkwright P, Abinun M, Cant A . Mevalonic aciduria cured by bone marrow transplantation. N Engl J Med. 2007; 357(13):1350. DOI: 10.1056/NEJMc072018. View

18.

Drenth J, Haagsma C, van der Meer J . Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore). 1994; 73(3):133-44. View

19.

Simon A, Drewe E, van der Meer J, Powell R, Kelley R, Stalenhoef A . Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther. 2004; 75(5):476-83. DOI: 10.1016/j.clpt.2004.01.012. View

20.

Bodar E, Kuijk L, Drenth J, van der Meer J, Simon A, Frenkel J . On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis. 2011; 70(12):2155-8. DOI: 10.1136/ard.2011.149922. View